ArticleInfectious medicine2025
MCPyV small T antigen enhances HPV16 oncogene expression, promotes Ca Ski cell proliferation, and reduces 5-fluorouracil-induced apoptosis in cervical cancer cells.
Article in Infectious medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer is primarily associated with persistent infection by high-risk human papillomaviruses (HR-HPVs), whose oncoproteins modulate key cellular pathways involved in proliferation and apoptosis. Merkel cell polyomavirus (MCPyV) has also been detected in cervical tissues, and its small T (sT) protein shares functional similarities with HR-HPV oncoproteins, suggesting a potential role in tumorigenesis. Methods: This study investigated whether MCPyV sT reduces 5-fluorouracil (5-FU)-induced apoptosis and influences HPV16 oncogene expression and proliferation in Ca Ski cells. The MCPyV sT gene was cloned into a mammalian expression vector, transfected into Ca Ski cells, and confirmed by western blotting. Cytotoxicity assays assessed the effects of MCPyV sT on 5-FU-treated cells, while RT-qPCR quantified viral oncogene expression. Annexin V/PI flow cytometry and Ki-67 immunostaining were used to evaluate apoptosis and proliferation. Results: MCPyV sT expression enhanced cell viability, increased the IC50 of 5-FU, and significantly reduced 5-FU-induced apoptosis. It also markedly upregulated HPV Conclusions: These findings underscore the potential cooperative effects of viral oncoproteins from distinct viruses in driving therapeutic resistance, highlighting the need for further research into their molecular interactions to inform targeted cervical cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.